Biopharmaceutical giant AstraZeneca has announced it is introducing advanced diagnostic testing for lung cancer in Kenya and Nigeria.
AstraZeneca said it is enhancing molecular testing infrastructure, collaborating with Moi Teaching and Referral Hospital (MTRH) and Nigeria’s Federal Ministry of Health.
In celebrations to mark World Cancer Day 2025, AstraZeneca reaffirmed its commitment to advancing early detection, innovative treatments, and holistic patient care under this year’s theme, “United by Unique.”
“This theme highlights the importance of patient-centered care, innovative approaches to improving outcomes, and the power of collaboration in advancing cancer care,” the firm said in a statement.
In South Africa, AstraZeneca has partnered with Medsol AI Solutions to launch Project Flamingo, an AI-driven healthcare innovation that enables real-time breast ultrasound scans and predictive analysis to improve early breast cancer detection in underserved communities.
AstraZeneca said the AI-powered app has demonstrated 97.6 per cent accuracy in predicting malignancies, supporting early detection efforts and helping ease pressure on public health systems.
“We are committed to advancing innovation in oncology care through early detection and precision diagnostics,” said Khomotso Mashilane, Medical Director at AstraZeneca.
He added that by leveraging cutting-edge technologies, developing patient-centred solutions, and fostering meaningful partnerships, AstraZeneca aims to empower patients and healthcare providers to improve outcomes and enhance quality of life.
“On this World Cancer Day, we honour every patient’s unique journey and reaffirm our dedication to advancing science and delivering meaningful care,” he stated.
AstraZeneca’s Cancer Care Africa programme, launched in Kenya with key partners, including the Ministry of Health seeks to enhance diagnostics, empower patients, and improve access to advanced cancer treatments.
Cancer remains a leading global cause of death, with delayed diagnoses and limited access to care, worsening outcomes.
The World Health Organization (WHO) estimates cancer mortality in sub-Saharan Africa could nearly double by 2030.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its medicines are used by millions of patients worldwide.
AstraZeneca focuses on the discovery, development, and commercialisation of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, and respiratory and immunology.